Allogene Therapeutics, Inc.

Some of the best links we picked up around the internet

CMN Weekly (14 March 2025) - Your Weekly CRISPR...

CMN Weekly

Mar. 14, 2025

Some of the best links we picked up around the internet

CMN Weekly (28 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 28, 2025

Some of the best links we picked up around the internet

CMN Weekly (14 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 14, 2025

Some of the best links we picked up around the internet

CMN Weekly (31 January 2025) - Your Weekly CRISPR...

CMN Weekly

Jan. 31, 2025

Some of the best links we picked up around the internet

Allogene's Dual-Acting CAR T Candidate ALLO-329...

CMN Clinical

Jan. 29, 2025

The FDA has cleared Allogene Therapeutics' IND application for ALLO-329, a novel dual-targeting CAR T cell therapy designed to treat multiple...

CMN Weekly (22 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 22, 2024

Some of the best links we picked up around the internet

CMN Weekly (15 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 15, 2024

Some of the best links we picked up around the internet

Allogene Therapeutics, Inc.

Large B-cell lymphoma, LBCL, (NCT06500273)
Sponsors:
Allogene Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Large B Cell Lymphoma, LBCL, (NCT05714345)
Sponsors:
Allogene Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Large B-Cell Lymphoma, LBCL, (NCT04416984)
Sponsors:
Allogene Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Multiple Myeloma, MM, (NCT05000450)
Sponsors:
Allogene Therapeutics, Inc.

IND Enabling

Phase I

Phase II

Phase III

Renal Cell Carcinoma, RCC, (NCT04696731)
Sponsors:
Allogene Therapeutics, Inc.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Non-Hodgkin Lymphoma, NHL, (NCT03939026)
Sponsors:
Allogene Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Multiple Myeloma, MM, (NCT04093596)
Sponsors:
Allogene Therapeutics

IND Enabling

Phase I

Phase II

Phase III